Immunodominance of poxviral-specific CTL in a human trial of recombinant-modified vaccinia Ankara
Many recombinant poxviral vaccines are currently in clinical trials for cancer and infectious diseases. However, these agents have failed to generate T cell responses specific for recombinant gene products at levels comparable with T cell responses associated with natural viral infections. The recent identification of vaccinia-encoded CTL epitopes, including a new epitope described in this study, allows the simultaneous comparison of CTL responses specific for poxviral and recombinant epitopes....[Show more]
|Collections||ANU Research Publications|
|Source:||Journal of Immunology|
|01_Smith_Immunodominance_of_2005.pdf||504.87 kB||Adobe PDF||Request a copy|
Items in Open Research are protected by copyright, with all rights reserved, unless otherwise indicated.